Bharat Biotech recruits 23,000 volunteers for Phase III trials of its coronavirus vaccine

The Phase III human clinical trials of Covaxin began mid-November, targeted to be done in 26,000 volunteers and it is the countrys first and only Phase III efficacy study for a COVID-19 vaccine, and the largest phase III efficacy trial ever conducted for any vaccine in India, a press release from the vaccine maker said on Saturday night.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/38O5jfe
via IFTTT